Driving a decade of change: HIV/AIDS, patents and access to medicines for all

Since 2000, access to antiretroviral drugs to treat HIV infection has dramatically increased to reach more than five million people in developing countries. Essential to this achievement was the dramatic reduction in antiretroviral prices, a result of global political mobilization that cleared the way for competitive production of generic versions of widely patented medicines.Global trade rules agreed upon in 1994 required many developing countries to begin offering patents on medicines for the first time. Government and civil society reaction to expected increases in drug prices precipitated a series of events challenging these rules, culminating in the 2001 World Trade Organization's Doha Declaration on the Agreement on Trade-Related Aspects of Intellectual Property Rights and Public Health. The Declaration affirmed that patent rules should be interpreted and implemented to protect public health and to promote access to medicines for all. Since Doha, more than 60 low- and middle-income countries have procured generic versions of patented medicines on a large scale.Despite these changes, however, a "treatment timebomb" awaits. First, increasing numbers of people need access to newer antiretrovirals, but treatment costs are rising since new ARVs are likely to be more widely patented in developing countries. Second, policy space to produce or import generic versions of patented medicines is shrinking in some developing countries. Third, funding for medicines is falling far short of needs. Expanded use of the existing flexibilities in patent law and new models to address the second wave of the access to medicines crisis are required.One promising new mechanism is the UNITAID-supported Medicines Patent Pool, which seeks to facilitate access to patents to enable competitive generic medicines production and the development of improved products. Such innovative approaches are possible today due to the previous decade of AIDS activism. However, the Pool is just one of a broad set of policies needed to ensure access to medicines for all; other key measures include sufficient and reliable financing, research and development of new products targeted for use in resource-poor settings, and use of patent law flexibilities. Governments must live up to their obligations to protect access to medicines as a fundamental component of the human right to health.

[1]  D. Daley PATENTS AND PILLS , POWER AND PROCEDURE : THE NORTH-SOUTH POLITICS OF PUBLIC HEALTH IN THE WTO , 2003 .

[2]  N. Michael,et al.  Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.

[3]  P. Goldberg,et al.  Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India , 2003, The American economic review.

[4]  Bunyan S. Womble,et al.  Non-voluntary Licensing of Patented Inventions Historical Perspective, Legal Framework under TRIPS, and an Overview of the Practice in Canada and the USA , 2003 .

[5]  Andrés Guadamuz González,et al.  Information Feudalism: Who owns the Knowledge Economy? , 2004, Int. J. Law Inf. Technol..

[6]  H. Leufkens,et al.  Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. , 2009, Bulletin of the World Health Organization.

[7]  M. Peeters,et al.  Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial , 2004, The Lancet.

[8]  P. Hunt Right to the highest attainable standard of health , 2006, The Lancet.

[9]  A. Rodgers,et al.  Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. , 2004, Bulletin of the World Health Organization.

[10]  C. Fink,et al.  Intellectual Property and Development: Lessons from Recent Economic Research , 2005 .

[11]  C. Deere The Implementation Game: The TRIPS Agreement and the Global Politics of Intellectual Property Reform in Developing Countries , 2009 .

[12]  A. Attaran,et al.  Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa? , 2001, JAMA.

[13]  R. A. Smith,et al.  Drugs into Bodies: Global AIDS Treatment Activism , 2006 .

[14]  W. Brouwer,et al.  Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the Developing World , 2010, PLoS medicine.

[15]  E. Torreele,et al.  Global framework on essential health R&D , 2006, The Lancet.

[16]  E. Hoen The global politics of pharmaceutical monopoly power: drug patents, access, innovation and the application of the WTO Doha Declaration on TRIPS and public health , 2009 .

[17]  N. Ford,et al.  Pricing of drugs and donations: options for sustainable equity pricing , 2001, Tropical medicine & international health : TM & IH.

[18]  L. Helfer Regime Shifting: The TRIPs Agreement and New Dynamics of International Intellectual Property Lawmaking , 2003 .

[19]  Susan K. Sell The Global IP Upward Ratchet, Anti-Counterfeiting and Piracy Enforcement Efforts: The State of Play , 2010 .

[20]  C. Correa Implications of bilateral free trade agreements on access to medicines. , 2006, Bulletin of the World Health Organization.

[21]  A. Kesselheim,et al.  Gene patenting--is the pendulum swinging back? , 2010, The New England journal of medicine.

[22]  Tim Hubbard,et al.  A New Trade Framework for Global Healthcare R&D , 2004, PLoS biology.

[23]  Susan K. Sell,et al.  Using Ideas Strategically: The Contest Between Business and NGO Networks in Intellectual Property Rights , 2004 .

[24]  M. Dybul,et al.  Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. , 2010, JAMA.

[25]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[26]  M. Pugatch The intellectual property debate : perspectives from law, economics and political economy , 2006 .

[27]  Jeffrey D Sachs,et al.  Expansion of cancer care and control in countries of low and middle income: a call to action , 2010, The Lancet.

[28]  E. Kapstein,et al.  Making Markets for Merit Goods: The Political Economy of Antiretrovirals , 2010 .

[29]  M. A. Oliveira,et al.  Intellectual property in the context of the WTO TRIPS agreement: challenges for public health , 2004 .

[30]  Ellen Diedrichsen,et al.  A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries , 2010, Journal of the International AIDS Society.

[31]  P. Hunt Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, Paul Hunt , 2005 .

[32]  D. Yulianti Hegemoni Epistemic Community Dalam Program Harm Reduction Unaids (Joint United Nations Programme On Hiv/Aids): Studi Pada Lsm Rumah Cemara , 2010 .

[33]  C. Correa Do patents work for public health? , 2006, Bulletin of the World Health Organization.

[34]  Frederick M. Abbott Seizure of Generic Pharmaceuticals in Transit Based on Allegations of Patent Infringement: A Threat to International Trade, Development and Public Welfare , 2009 .

[35]  Organización Mundial de la Salud Global strategy and plan of action on public health, innovation and intellectual property , 2009 .

[36]  Michael Worth Médecins Sans Frontières/Doctors Without Borders , 2013 .

[37]  M. Heller,et al.  Can Patents Deter Innovation? The Anticommons in Biomedical Research , 1998, Science.

[38]  Carolyn Deere Birkbeck The Implementation Game: The TRIPS Agreement and the Global Politics of Intellectual Property Reform in Developing Countries , 2008 .

[39]  C. Patel A discussion paper , 2010 .

[40]  J. Morin Daniel Gervais, The TRIPS Agreement : Drafting History and Analysis, London, Sweet and Maxwell, 2003 , 2003 .

[41]  N. Ford,et al.  Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand , 2007, AIDS.

[42]  Frederick M. Abbott The Enduring Enigma of TRIPS: A Challenge for the World Economic System , 1998 .

[43]  Michelle L. Childs Towards a Patent Pool for HIV Medicines: The Background , 2010, The open AIDS journal.

[44]  A. Banerjee,et al.  The Health Impact Fund: incentives for improving access to medicines , 2010, The Lancet.

[45]  J. Travis Prizes Eyed to Spur Medical Innovation , 2008, Science.

[46]  Frederick M. Abbott,et al.  World Trade Organization Accession Agreements: Intellectual Property Issues , 2007 .

[47]  Susan K. Sell Private Power, Public Law: The Globalization of Intellectual Property Rights , 2003 .

[48]  Keith E. Maskus,et al.  Intellectual property rights in the global economy , 2000 .

[49]  S. Leckie,et al.  14. CESCR General Comment No. 14 (2000) on the Right to the Highest Attainable Standard of Health (Article 12) , 2006 .

[50]  Heidi L. Williams,et al.  Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. , 2007, Health economics.

[51]  H. Grabowski,et al.  Developing drugs for developing countries. , 2006, Health affairs.

[52]  Minsky,et al.  From the New York Times Magazine , 1979 .

[53]  S. Epstein Impure Science: AIDS, Activism, and the Politics of Knowledge , 1998 .

[54]  E. Cameron Patents and Public Health: Principle, Politics and Paradox , 2004 .

[55]  John Travis Science by the Masses , 2008, Science.

[56]  M. Kyle,et al.  Open Access RESEARCH , 2010 .

[57]  D. Kerrigan The politics and history of AIDS treatment in Brazil , 2010 .

[58]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[59]  Tatum Anderson,et al.  Confusion over counterfeit drugs in Uganda , 2009, The Lancet.

[60]  J. Bermudez,et al.  The UNITAID Patent Pool Initiative: Bringing Patents Together for the Common Good , 2010, The open AIDS journal.

[61]  L. Lynen,et al.  Do patents prevent access to drugs for HIV in developing countries? , 2002, Journal of the American Medical Association (JAMA).

[62]  A. Binagwaho,et al.  Task Shifting for Scale-up of HIV Care: Evaluation of Nurse-Centered Antiretroviral Treatment at Rural Health Centers in Rwanda , 2009, PLoS medicine.

[63]  P. Bond Globalization, Pharmaceutical Pricing, and South African Health Policy: Managing Confrontation with U.S. Firms and Politicians , 1999, International journal of health services : planning, administration, evaluation.

[64]  D. Foray Technology Transfer in the TRIPS Age: The Need for New Types of Partnerships between the Least Developed and Most Advanced Economies , 2009 .

[65]  TAkING STOCk,et al.  Task shifting to tackle health worker shortages , 2007 .

[66]  Geoff Tansey,et al.  Negotiating health : intellectual property and access to medicines , 2006 .

[67]  B. Hirschel,et al.  HIV drugs for treatment, and for prevention , 2010, The Lancet.

[68]  L. Reichman,et al.  Fixed-Dose Combinations of Antituberculous Medications To Prevent Drug Resistance , 1995, Annals of Internal Medicine.

[69]  C. May The Global Political Economy of Intellectual Property Rights: The New Enclosures? , 2000 .

[70]  M. Selgelid,et al.  Do patents prevent access to drugs for HIV in developing countries? , 2002, JAMA.

[71]  Graham Dutfield,et al.  Intellectual Property Rights and the Life Science Industries: A Twentieth Century History , 2003 .

[72]  Daniel J. Gervais,et al.  The TRIPS agreement: Drafting history and analysis , 1998 .

[73]  A. Dennis Intellectual Property Rights, the WTO and Developing Countries: The TRIPS Agreement and Policy Options , 2002 .

[74]  Prizes for innovation of new medicines and vaccines. , 2009, Annals of health law.

[75]  A. Kesselheim Drug development for neglected diseases - the trouble with FDA review vouchers. , 2008, The New England journal of medicine.

[76]  黄亚明,et al.  Journal of the International AIDS Society , 2017 .